(Q40543430)

21 September 2017

title

Histologic confirmation of lesions identified by Prostascint scan following definitive treatment (English)

1 reference

21 September 2017

Carlos E Bermejo

1

1 reference

21 September 2017

John Coursey

2

1 reference

21 September 2017

Joseph Basler

3

1 reference

21 September 2017

Mark Austenfeld

4

1 reference

21 September 2017

Ian Thompson

5

1 reference

21 September 2017

publication date

1 September 2003

1 reference

21 September 2017

1 reference

21 September 2017

volume

21

1 reference

21 September 2017

issue

5

1 reference

21 September 2017

page(s)

349-52; discussion 353

1 reference

111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900253-3

7 January 2021

Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900253-3

7 January 2021

Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900253-3

7 January 2021

Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900253-3

7 January 2021

ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900253-3

7 January 2021

Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900253-3

7 January 2021

Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900253-3

7 January 2021

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900253-3

7 January 2021

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900253-3

7 January 2021

Monoclonal antibody 7E11.C5 staining of viable LNCaP cells

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900253-3

7 January 2021

10.1016/S1078-1439(02)00253-3

Identifiers

DOI

1 reference

21 September 2017

1 reference